results
Jump to
57 Results Found
  • Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher Jan 18, 2021 10:47 PM IST

    Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.

  • Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies Jun 03, 2020 07:46 AM IST

    Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies

    The stock shot up 149 percent from its March lows especially after increased focus on healthcare worldwide due to COVID-19 crisis.

  • Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay Oct 14, 2019 03:47 PM IST

    Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay

    Net Sales are expected to increase by 18.8 percent Y-o-Y (up 3.7 percent Q-o-Q) to Rs. 5,645.7 crore, according to Emkay.

  • Aurobindo Pharma Q4 PAT seen up 17.8% YoY to Rs. 641.6 cr: Kotak Apr 17, 2019 03:10 PM IST

    Aurobindo Pharma Q4 PAT seen up 17.8% YoY to Rs. 641.6 cr: Kotak

    Net Sales are expected to increase by 26.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 5,121.6 crore, according to Kotak.

  • Aurobindo Pharma Q4 PAT seen up 18.2% YoY to Rs. 624.9 cr: Prabhudas Lilladher Apr 12, 2019 12:45 PM IST

    Aurobindo Pharma Q4 PAT seen up 18.2% YoY to Rs. 624.9 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 25.9 percent Y-o-Y (down 3 percent Q-o-Q) to Rs. 5,020.7 crore, according to Prabhudas Lilladher.

  • Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings Feb 11, 2019 01:08 PM IST

    Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings

    Aurobindo has maintained its guidance of 30 percent YoY growth in injectable sales. Further, company filed 10 ANDAs, including 4 injectables, taking the cumulative ANDAs pending for approval to 122

  • Aurobindo Pharma Q3 preview: Profit may get a boost; outlook on US business key Feb 07, 2019 07:54 AM IST

    Aurobindo Pharma Q3 preview: Profit may get a boost; outlook on US business key

    The company will declare its results today. Analysts suggest one to focus on US business growth and upcoming product announcements.

  • Aurobindo Q3 PAT seen up 11.5% YoY to Rs. 729 cr: Sharekhan Jan 18, 2019 01:51 PM IST

    Aurobindo Q3 PAT seen up 11.5% YoY to Rs. 729 cr: Sharekhan

    Net Sales are expected to increase by 12.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 4,888 crore, according to Sharekhan.

  • Aurobindo Pharma Q3 PAT seen up 13.8% YoY to Rs. 669.1 cr: ICICI Direct Jan 11, 2019 05:23 PM IST

    Aurobindo Pharma Q3 PAT seen up 13.8% YoY to Rs. 669.1 cr: ICICI Direct

    Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila Jan 04, 2019 10:45 AM IST

    Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

    For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

  • Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance Nov 12, 2018 08:18 AM IST

    Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance

    Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.

  • Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities Oct 17, 2018 05:39 PM IST

    Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities

    Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.

  • Aurobindo Q2 PAT may dip 23.1% YoY to Rs. 600 cr: Sharekhan Oct 16, 2018 06:55 PM IST

    Aurobindo Q2 PAT may dip 23.1% YoY to Rs. 600 cr: Sharekhan

    Net Sales are expected to increase by 6.3 percent Y-o-Y (up 10.9 percent Q-o-Q) to Rs. 4,714 crore, according to Sharekhan.

  • Aurobindo Pharma Q2 PAT may dip 23% YoY to Rs. 601.9 cr: ICICI Direct Oct 12, 2018 03:54 PM IST

    Aurobindo Pharma Q2 PAT may dip 23% YoY to Rs. 601.9 cr: ICICI Direct

    Net Sales are expected to increase by 4.6 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 4,638.9 crore, according to ICICI Direct.

  • Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz Aug 25, 2018 10:26 AM IST

    Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz

    Emkay Global, in its report, observed that cycling pressure in US market will start waning ahead, but structural pressures will still persist.

  • Aurobindo Pharma Q1 PAT seen up 7.5% YoY to Rs. 557.3 cr: Kotak Jul 18, 2018 02:06 PM IST

    Aurobindo Pharma Q1 PAT seen up 7.5% YoY to Rs. 557.3 cr: Kotak

    Net Sales are expected to increase by 12 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,119 crore, according to Kotak.

  • Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz Jul 12, 2018 09:42 PM IST

    Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

    "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

  • Aurobindo Pharma Q4 PAT seen up 10.7% YoY to Rs. 570 cr: HDFC Securities Apr 20, 2018 01:01 PM IST

    Aurobindo Pharma Q4 PAT seen up 10.7% YoY to Rs. 570 cr: HDFC Securities

    Net Sales are expected to increase by 13.8 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs. 4,100 crore, according to HDFC Securities.

  • Aurobindo Q4 PAT seen up 25.3% YoY to Rs. 648.2 cr: Edelweiss Apr 16, 2018 05:55 PM IST

    Aurobindo Q4 PAT seen up 25.3% YoY to Rs. 648.2 cr: Edelweiss

    Net Sales are expected to increase by 19 percent Y-o-Y to Rs. 4,334.4 crore, according to Edelweiss.

  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key Apr 12, 2018 05:53 PM IST

    Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

    Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

  • Aurobindo Pharma may post 18% growth in Q3 profit, US business seen up 12% Feb 07, 2018 12:28 PM IST

    Aurobindo Pharma may post 18% growth in Q3 profit, US business seen up 12%

    Europe and Rest of World sales are likely to grow 15-18 percent YoY while API business is likely to be flat.

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key Jan 18, 2018 08:36 AM IST

    Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

    As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

  • Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss Jan 11, 2018 04:06 PM IST

    Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss

    The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.

  • Aurobindo Pharma Q2 profit seen up 15% to Rs 696 cr, operating margin may grow 110 bps Nov 08, 2017 05:26 PM IST

    Aurobindo Pharma Q2 profit seen up 15% to Rs 696 cr, operating margin may grow 110 bps

    EBITDA (earnings before interest, tax, depreciation and amortisation) may increase 15.6 percent year-on-year to Rs 1,074.4 crore and margin may expand 110 basis points to 25.7 percent for quarter ended September 2017.

  • Aurobindo Pharma Q2 PAT seen up 11.1% YoY to Rs. 672.7 cr: Kotak Oct 13, 2017 05:31 PM IST

    Aurobindo Pharma Q2 PAT seen up 11.1% YoY to Rs. 672.7 cr: Kotak

    Net Sales are expected to increase by 6.9 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 4035.4 crore, according to Kotak.

Sections